Lenabasum (also known as ajulemic acid, 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab) is a
syntheticcannabinoid that shows
anti-fibrotic and
anti-inflammatory effects in
pre-clinical studies without causing a subjective "high".[1] Although its design was inspired by a
metabolite of
delta-9-THC known as
delta-9-THC-11-oic acid, lenabasum is an
analog of the
delta-8-THC metabolite delta-8-THC-11-oic acid.[2][3] It is being
developed for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis.[4] It does not share the
anti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve.[5] Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of the
CB2 receptor leading to production of specialized proresolving eicosanoids such as
lipoxin A4 and
prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced by
tetrahydrocannabinol.[6] Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases.[7] Development since been discontinued.[8]
References
^Burstein SH, Karst M, Schneider U, Zurier RB (August 2004). "Ajulemic acid: A novel cannabinoid produces analgesia without a "high"". Life Sciences. 75 (12): 1513–1522.
doi:
10.1016/j.lfs.2004.04.010.
PMID15240185.
^Vann RE, Cook CD, Martin BR, Wiley JL (February 2007). "Cannabimimetic properties of ajulemic acid". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 678–686.
doi:
10.1124/jpet.106.111625.
PMID17105826.
S2CID15593252.
^Mitchell VA, Aslan S, Safaei R, Vaughan CW (July 2005). "Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain". Neuroscience Letters. 382 (3): 231–235.
doi:
10.1016/j.neulet.2005.03.019.
PMID15925096.
S2CID582590.